Septic Shock Clinical Trial
Official title:
Cardiac Stress in Septic Shock - Biomarkers, Echocardiography and Outcome.
Septic shock is a major cause of death in intensive care. Septic shock is often dominated by
profound changes in organ functions, of which cardiac failure is one of the most severe. In
septic shock, biological markers of cardiac stress are often elevated. It is not known to
what extent this indicates structural damage to the heart, or in what way they correlate to
echocardiographic signs of heart failure.
Here, cardiac failure in ICU patients with septic shock is studied, using biological markers
of cardiac stress, inflammatory parameters and echocardiography.
Investigators hypothesize that biomarkers of cardiac stress correlate with echocardiographic
signs of heart failure, and that they can predict an increased risk of death.
Sepsis and septic shock are major health concerns worldwide. Sepsis is the consequence of
inflammatory processes and humoral and cellular reactions to severe infection. Its clinical
presentation is variable, with a continuum from a systemic response to infection to
fulminant disease refractory to resuscitation and with multiple organ failure. Septic shock
is the most severe form of sepsis and the leading cause of death in intensive care patients
with a high mortality despite modern resuscitation and treatment.
Septic shock is dominated clinically by circulatory changes presenting with profound
vasodilatation and hypotension. Cardiac output values are often seemingly normal, or even
enhanced, when compared with the physiological range. However, relative to the
vasodilatation, cardiac output is often not adequately enhanced. Thus, the degree of
myocardial depression in sepsis is often underestimated by the clinician, albeit a factor
that markedly increases mortality.
Septic cardiomyopathy typically engages both ventricles globally, and involves diminished
cardiac response to volume and circulating catecholamines. It is not primarily hypoxic, but
rather has a multifactorial origin. In survivors, it is typically reversible, but long-term
consequences are not known.
Cardiac biomarkers, i.e. troponins and natriuretic peptides, are all associated with worse
outcome in septic shock. Cardiac troponins are frequently elevated and correlate to the
duration of hypotension and the intensity of vasopressor support. Elevated natriuretic
peptides predict adverse outcome, and values are often markedly elevated even in seemingly
normal echocardiographic findings. It is not clear whether this indicates structural
myocardial damage, or rather demonstrate a global septic membrane leakage. Thus, with the
complexity of sepsis, combinations of cardiac biomarkers and markers of global inflammation
may provide a more robust tool for stratification and prognostication and for evaluation of
septic organ dysfunction. In clinical cardiology, combinations of biomarkers of myocardial
stress are used for stratification and prognostication of myocardial failure, but the role
of such multimarker panels in septic cardiomyopathy has not been studied.
Echocardiography is used clinically, and has been the focus of several studies, to
characterize septic cardiomyopathy. Echocardiographic signs of systolic dysfunction has been
the main focus of previous investigations, and the systolic component is the focus of modern
guidelines of clinical management in septic cardiomyopathy. The role of diastolic
dysfunction is gaining interest, with data suggesting higher mortality in patients with
diastolic dysfunction than in those with systolic dysfunction. To date, the correlation of
echocardiographic signs of systolic or diastolic dysfunction myocardial stress biomarker
panels, and the dynamics of any correlation, has not been studied.
The hypothesis of this study is that biological markers of cardiac stress correlate with
echocardiographic signs of cardiac failure, that they can predict outcome, and that they
correlate to conventional methods of outcome prediction.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A |